Advanced Oncotherapy (LON:AVO) issued its earnings results on Monday. The company reported GBX (9.83) (($0.12)) earnings per share for the quarter, missing the consensus estimate of GBX (8.90) (($0.11)) by GBX (0.93) (($0.01)), Bloomberg Earnings reports.

LON:AVO opened at GBX 26 ($0.32) on Tuesday. The firm has a market cap of $79.66 million and a P/E ratio of -1.86. The company has a current ratio of 2.16, a quick ratio of 0.79 and a debt-to-equity ratio of 55.71. The stock’s 50 day simple moving average is GBX 26.68 and its 200-day simple moving average is GBX 32.10. Advanced Oncotherapy has a 12-month low of GBX 20 ($0.25) and a 12-month high of GBX 44.50 ($0.55).

About Advanced Oncotherapy

Advanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. The company operates through two segments, Proton Therapy and Healthcare Related Properties. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer.

See Also: FinTech

Receive News & Ratings for Advanced Oncotherapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy and related companies with's FREE daily email newsletter.